Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Skin Neoplasms × binimetinib × Clear all

Phase

Phase 3 3 Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 18 Brain Neoplasms 6 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Ovarian Neoplasms 2 Multiple Myeloma 2 Leukemia, Hairy Cell 2 Hematologic Neoplasms 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Skin Neoplasms 1 Recurrence 1 Peripheral Nervous System Neoplasms 1 Noonan Syndrome 5 1 Neurofibromatosis 1 1 Neurofibromatoses 1 Neurofibroma, Plexiform 1 Neurofibroma 1 Lymphoma 1 Lymphatic Metastasis 1 Leukemia, Myeloid, Acute 1 Hereditary Sensory and Autonomic Neuropathies 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1

Interventions

aldesleukin 15 Cyclophosphamide 13 fludarabine phosphate 10 fludarabine 10 Interleukin-2 10 Nivolumab 7 pembrolizumab 5 Ipilimumab 5 cemiplimab 4 Fluorouracil 4 Aminolevulinic Acid 4 sonidegib 3 Temozolomide 3 Surgical Procedures, Operative 3 Radiotherapy 3 zanolimumab 2 trametinib 2 talabostat 2 montanide ISA 51 2 dabrafenib 2 Whole-Body Irradiation 2 Tablets 2 Semaxinib 2 Radiation 2 Petrolatum 2 Peptides 2 Gefitinib 2 Cisplatin 2 Cetuximab 2 Capecitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05926960 2026-03-09

PORTSIDE

Pfizer

Phase 2 Terminated

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡